The Greater Phoenix Community Clinical Oncology Program (GPCCOP)is a consortium of five hospitals with 67 investigations led by principal investigator David K. King, M.D. Dr. King and many of the investigators have been associated with the CCOP since its initial planning stage in 1982. The continuing long-term goals and specific aims of the GPCCOP include: 1) increased clinical research activities; 2) access to additional clinical trials; 3) further development of cancer control research initiatives and patient accrual; 4) maintenance of quality data management; 5) pharmacy resources to coordinate and manage drug distribution; 6) involvement of primary care physicians in state-of-the- art cancer management and education; and 7) continued development of data management systems to support NCI evaluations. GPCCOP's organizational structure requires the involvement of the Co- Principal Investigators and hospital administrators from each of the participating institutions in the planning and policy-making decisions of the CCOP. The physicians, nurses and administrative staff have active roles in guiding the GPCCOP toward attainment of its goals. This experienced team has demonstrated their commitment and ability to accrue patients to both therapeutic and cancer control protocols while maintaining high levels of quality control and timely submissions. GPCCOP's data management systems were recognized by SWOG in 1991 with the Outstanding Achievement Award. Additional investigators, specializing in medical and radiation oncology, have been recruited to the GPCCOP to ensure the availability of total patient care for the 3000 average new patients seen each year. By adding investigators from the Tucson area and adding the GOG as a research base, a higher level of participation is expected. The above resources, the placement of 347 patients on treatment protocols and 1097 patients on cancer control trials during the period 1989 to present demonstrate GPCCOP's preparedness to continue its active participation in NCI's Community Oncology Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA035262-16
Application #
2894578
Study Section
Special Emphasis Panel (ZCA1-RLB-7 (J3))
Program Officer
Dunn, Barbara K
Project Start
1983-09-01
Project End
2003-05-31
Budget Start
1999-06-01
Budget End
2000-05-31
Support Year
16
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Banner Good Samaritan Medical Center
Department
Type
DUNS #
110443561
City
Phoenix
State
AZ
Country
United States
Zip Code
85006
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13

Showing the most recent 10 out of 67 publications